Oncology & Cancer

First Phase III trial of an alpha-pharmaceutical

Until recently, options for patients with bone metastases from advanced prostate cancer have been very limited. But now the first Phase III study of an alpha-pharmaceutical in these patients has shown that it can prolong ...

Oncology & Cancer

High-impact radiopeptide therapy halts neuroendocrine cancer

Research introduced at SNM's 58th Annual Meeting could be a sign of hope for patients with neuroendocrine cancer not responding well to standard therapies. Most radiotherapies use medical isotopes that emit beta radiation. ...

page 2 from 2